Pharmaceutical formulations of desmopressin
AssigneeFerring B.V.
InventorsAnders Nilsson, Hans Lindner, Jørgen Wittendorff
Life of this patent
Estimating the term…
Abstract
Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Claims15
An orodispersible pharmaceutical dosage form of desmopressin comprising:
- desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and
- one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,
- wherein the dosage form exhibits a mean elimination half-life of desmopressin after administration of about 2.8 to 3 hours after the maximum plasma concentration is reached.
An orodispersible pharmaceutical dosage form of desmopressin comprising:
- desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and
- one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,
- wherein the dosage form exhibits a desmopressin bioavailability after administration of from greater than 0.1% to 0.38%.
An orodispersible pharmaceutical dosage form of desmopressin comprising:
- desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and
- one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,
- wherein the dosage form exhibits a desmopressin bioavailability of from 0.23% to 0.38%.
Dependencies are inferred from the claim text.